目的 评价照射窄谱紫外线B(narrowband ultraviolet B,NB-UVB)联合盐酸西替利嗪治疗慢性荨麻疹的疗效及安全性。方法 选择2016-01至2018-01 64例慢性荨麻疹患者,随机分为两组。治疗组(32例) 照射NB-UVB,同时口服盐酸西替利嗪,对照组(32例)单纯口服盐酸西替利嗪。疗程均为1个月。治疗前及治疗后1、2、4周进行随访,评价疗效及不良反应。结果 治疗后,治疗组与对照组在第1,2和4周症状指标总积分中均有显著下降(P＜0.05)。第4周总体效果评价,治疗组痊愈率为59.4%,有效率为93.8%;对照组痊愈率为37.5%,有效率为62.5%,两组有效率差异具有统计学意义(P＜0.05)。结论 照射NB-UVB联合口服盐酸西替利嗪治疗慢性荨麻疹近期疗效显著,其临床效果明显优于单纯口服盐酸西替利嗪片治疗。
Abstract
Objective To compare the efficacy and safety of narrowband ultraviolet B (NB-UVB) combined with cetirizine hydrochloride in the treatment of chronic urticaria.Methods Sixty-four patients with chronic urticaria were selected and divided into two groups: the treatment group with 32 patients subjected to NB-UVB combined with oral cetirizine hydrochloride and the control group composed of 32 patients administrated with oral cetirizine hydrochloride. The two groups were compared according to the urticaria total severity score (TSS) before and after treatment. All the patients were followed up for 1, 2 and 4 weeks before and after treatment, and the efficacy and side effects were evaluated.Results After treatment, the total scores of symptoms and signs decreased significantly in both groups at 1,2 and 4 weeks (P＜0.05).The cure rate in the treatment group was 59.4% and the effective rate was 93.8%, compared to 37.5% and 62.5% in the control group after four weeks of treatment. The difference in the effective rate between the two groups was statistically significant (P＜0.05).Conclusions NB-UVB in combination with cetirizine hydrochloride is effective for chronic urticaria, with a lower rate of adverse events.
关键词
慢性荨麻疹 /
盐酸西替利嗪 /
窄谱紫外线B
Key words
chronic urticaria /
cetirizine /
NB-UVB
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Bajaj A K, Saraswat A, Upadhyay A, et al. Autologous serum therapy in chronic urticaria: old wine in a new bottle [J]. Indian J Dermatol Venereol Leprol, 2008,74(2):109-113.
[2] Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF EAACI/GA2LEN/EDF guideline: management of urticaria [J]. Allergy, 2006,61(3):321-331.
[3] Khafagy N H,Salem S A,Ghaly E G. Comparative study of systemic psoralen and ultraviolet a and narrowband ultraviolet B in treatment of chronic urticaria [J]. Photodermatol Photoimmunol Photomed, 2013, 29(1):12-17.
[4] Venarske D,deShazo R D. Molecular mechanisms of allergic diseases [J]. South Med J, 2003, 96(11):1049-1054.
[5] Zhang L, Cheng L, Hong J G. The clinical use of cetirizine in the treatment of allergic rhinitis[J]. Pharmacology, 2013, 92(1-2):14-25.
[6] Gambichler T, Breuckmann F, Boms S, et al. Narrowband UVB phototherapy in skin conditions beyond psoriasis [J]. J Am Acad Dermatol, 2005, 52(4):660-670.
[7] El-Ghorr A A, Norval M. Biological effects of narrow-band (311nm TL01) UVB irradiation: a review [J]. J Photochem Photobiol B, 1997, 38(2-3): 99-106.
[8] Szepietowski J C, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus [J]. Med Hypotheses, 2002, 58(2): 167-170.
[9] Sigmundsdottir H, Johnston A, Gudjonsson J E, et al. Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells [J]. Arch Dermatol Res, 2005, 297(1):39-42.
[10] Engin B, Ozdemir M, Balevi A, et al. Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial [J]. Acta Derm Venereol, 2008, 88(3):247-251.
[11] Berroeta L, Clark C, Ibbotson S H, et al. Narrow-band (TL-01) ultraviolet B phototherapy for chronic urticaria [J]. Clin Exp Dermatol, 2004,29(1):97-98.
PDF(555 KB)
